Ann: Kazia commences recruitment to GBM AGILE, page-9

WOW, Check out Howard Colman, MD, PhD, above tweet, describing key innovations for GBM AGILE.
He states the study framework could potentially speed up the FDA approval process by allowing confirmatory data accrued during the ongoing study arm for the drug to be used and submitted to the FDA to consider an approval. This allows the drug to reach patients quicker than the time it takes for FDA approval from traditional trials.

Regards.